Diabetic kidney disease: A clinical update from Kidney Disease: Improving Global Outcomes

Mark E. Molitch; Amanda I. Adler; Allan Flyvbjerg; Robert G. Nelson; Wing Yee So; Christoph Wanner; Bertram L. Kasiske; David C. Wheeler; Dick De Zeeuw; Carl E. Mogensen

doi:10.1038/ki.2014.128

Diabetic kidney disease: A clinical update from Kidney Disease: Improving Global Outcomes

Mark E. Molitch, Amanda I. Adler, Allan Flyvbjerg, Robert G. Nelson, Wing Yee So, Christoph Wanner, Bertram L. Kasiske, David C. Wheeler, Dick De Zeeuw, Carl E. Mogensen

Medicine - Renal and Hypertension Division

Research output: Contribution to journal › Article › peer-review

121 Scopus citations

Abstract

The incidence and prevalence of diabetes mellitus (DM) continue to grow markedly throughout The world, due primarily to The increase in type 2 DM (T2DM). Although improvements in DM and hypertension management have reduced The proportion of diabetic individuals who develop chronic kidney disease (CKD) and progress to end-stage renal disease (ESRD), The sheer increase in people developing DM will have a major impact on dialysis and transplant needs. This KDIGO conference addressed a number of controversial areas in The management of DM patients with CKD, including aspects of screening for CKD with measurements of albuminuria and estimated glomerular filtration rate (eGFR); defining treatment outcomes; glycemic management in both those developing CKD and those with ESRD; hypertension goals and management, including blockers of The renin-angiotensin-aldosterone system; and lipid management.

Original language	English (US)
Pages (from-to)	20-30
Number of pages	11
Journal	Kidney international
Volume	87
Issue number	1
DOIs	https://doi.org/10.1038/ki.2014.128
State	Published - Jan 3 2015

Bibliographical note

Funding Information:
This conference was sponsored by KDIGO with support from Biocon. This work was also supported in part by the Intramural Program of the National Institute of Diabetes and Digestive and Kidney Diseases.

Funding Information:
DdZ declared having served as a consultant for and received honoraria (to employer) from Abbott, AbbVie, Astellas, ChemoCentryx, Johnson & Johnson, Merck Sharp & Dohme, Pfizer, and Reata. CEM declaring having received speaker honoraria from Merck Sharp & Dohme. MEM declared having received consultancy fees from Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Janssen, Merck, Novartis, and Novo Nordisk, and research funding from Bayer, Novartis, and Novo Nordisk. CW declared having received speaker honoraria from Astellas (Japan), Pfizer, Merck, and Merck Sharpe & Dohme. DCW declared having received consultancy fees from Abbvie, Amgen, Astellas, Baxter, F Hoffmann-La Roche, Janssen, Merck Sharp & Dohme, Otsuka, and Vifor; research funding from AstraZeneca/British Heart Foundation, Kidney Research UK, Medical Research Council, Healthcare Quality Improvement Partnership; honoraria from Amgen and Otsuka. AIA, AF, BLK, RGN, and W-YS reported no relevant disclosures.

Publisher Copyright:
© 2015 International Society of Nephrology.

Copyright:
Copyright 2018 Elsevier B.V., All rights reserved.

Keywords

Albuminuria
blood pressure
diabetic kidney disease
glycemic control
lipid management

UN SDGs

This output contributes to the following Sustainable Development Goal(s)

Access

10.1038/ki.2014.128

Fingerprint Dive into the research topics of 'Diabetic kidney disease: A clinical update from Kidney Disease: Improving Global Outcomes'. Together they form a unique fingerprint.

Cite this

Diabetic kidney disease : A clinical update from Kidney Disease: Improving Global Outcomes. / Molitch, Mark E.; Adler, Amanda I.; Flyvbjerg, Allan; Nelson, Robert G.; So, Wing Yee; Wanner, Christoph; Kasiske, Bertram L.; Wheeler, David C.; De Zeeuw, Dick; Mogensen, Carl E.

In: Kidney international, Vol. 87, No. 1, 03.01.2015, p. 20-30.

Research output: Contribution to journal › Article › peer-review

@article{7f6e14a2976a4fcb9d3b26107b3d3bc9,

title = "Diabetic kidney disease: A clinical update from Kidney Disease: Improving Global Outcomes",

abstract = "The incidence and prevalence of diabetes mellitus (DM) continue to grow markedly throughout The world, due primarily to The increase in type 2 DM (T2DM). Although improvements in DM and hypertension management have reduced The proportion of diabetic individuals who develop chronic kidney disease (CKD) and progress to end-stage renal disease (ESRD), The sheer increase in people developing DM will have a major impact on dialysis and transplant needs. This KDIGO conference addressed a number of controversial areas in The management of DM patients with CKD, including aspects of screening for CKD with measurements of albuminuria and estimated glomerular filtration rate (eGFR); defining treatment outcomes; glycemic management in both those developing CKD and those with ESRD; hypertension goals and management, including blockers of The renin-angiotensin-aldosterone system; and lipid management.",

keywords = "Albuminuria, blood pressure, diabetic kidney disease, glycemic control, lipid management",

author = "Molitch, {Mark E.} and Adler, {Amanda I.} and Allan Flyvbjerg and Nelson, {Robert G.} and So, {Wing Yee} and Christoph Wanner and Kasiske, {Bertram L.} and Wheeler, {David C.} and {De Zeeuw}, Dick and Mogensen, {Carl E.}",

note = "Funding Information: This conference was sponsored by KDIGO with support from Biocon. This work was also supported in part by the Intramural Program of the National Institute of Diabetes and Digestive and Kidney Diseases. Funding Information: DdZ declared having served as a consultant for and received honoraria (to employer) from Abbott, AbbVie, Astellas, ChemoCentryx, Johnson & Johnson, Merck Sharp & Dohme, Pfizer, and Reata. CEM declaring having received speaker honoraria from Merck Sharp & Dohme. MEM declared having received consultancy fees from Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Janssen, Merck, Novartis, and Novo Nordisk, and research funding from Bayer, Novartis, and Novo Nordisk. CW declared having received speaker honoraria from Astellas (Japan), Pfizer, Merck, and Merck Sharpe & Dohme. DCW declared having received consultancy fees from Abbvie, Amgen, Astellas, Baxter, F Hoffmann-La Roche, Janssen, Merck Sharp & Dohme, Otsuka, and Vifor; research funding from AstraZeneca/British Heart Foundation, Kidney Research UK, Medical Research Council, Healthcare Quality Improvement Partnership; honoraria from Amgen and Otsuka. AIA, AF, BLK, RGN, and W-YS reported no relevant disclosures. Publisher Copyright: {\textcopyright} 2015 International Society of Nephrology. Copyright: Copyright 2018 Elsevier B.V., All rights reserved.",

year = "2015",

month = jan,

day = "3",

doi = "10.1038/ki.2014.128",

language = "English (US)",

volume = "87",

pages = "20--30",

journal = "Kidney International",

issn = "0085-2538",

publisher = "Nature Publishing Group",

number = "1",

}

TY - JOUR

T1 - Diabetic kidney disease

T2 - A clinical update from Kidney Disease: Improving Global Outcomes

AU - Molitch, Mark E.

AU - Adler, Amanda I.

AU - Flyvbjerg, Allan

AU - Nelson, Robert G.

AU - So, Wing Yee

AU - Wanner, Christoph

AU - Kasiske, Bertram L.

AU - Wheeler, David C.

AU - De Zeeuw, Dick

AU - Mogensen, Carl E.

N1 - Funding Information: This conference was sponsored by KDIGO with support from Biocon. This work was also supported in part by the Intramural Program of the National Institute of Diabetes and Digestive and Kidney Diseases. Funding Information: DdZ declared having served as a consultant for and received honoraria (to employer) from Abbott, AbbVie, Astellas, ChemoCentryx, Johnson & Johnson, Merck Sharp & Dohme, Pfizer, and Reata. CEM declaring having received speaker honoraria from Merck Sharp & Dohme. MEM declared having received consultancy fees from Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Janssen, Merck, Novartis, and Novo Nordisk, and research funding from Bayer, Novartis, and Novo Nordisk. CW declared having received speaker honoraria from Astellas (Japan), Pfizer, Merck, and Merck Sharpe & Dohme. DCW declared having received consultancy fees from Abbvie, Amgen, Astellas, Baxter, F Hoffmann-La Roche, Janssen, Merck Sharp & Dohme, Otsuka, and Vifor; research funding from AstraZeneca/British Heart Foundation, Kidney Research UK, Medical Research Council, Healthcare Quality Improvement Partnership; honoraria from Amgen and Otsuka. AIA, AF, BLK, RGN, and W-YS reported no relevant disclosures. Publisher Copyright: © 2015 International Society of Nephrology. Copyright: Copyright 2018 Elsevier B.V., All rights reserved.

PY - 2015/1/3

Y1 - 2015/1/3

N2 - The incidence and prevalence of diabetes mellitus (DM) continue to grow markedly throughout The world, due primarily to The increase in type 2 DM (T2DM). Although improvements in DM and hypertension management have reduced The proportion of diabetic individuals who develop chronic kidney disease (CKD) and progress to end-stage renal disease (ESRD), The sheer increase in people developing DM will have a major impact on dialysis and transplant needs. This KDIGO conference addressed a number of controversial areas in The management of DM patients with CKD, including aspects of screening for CKD with measurements of albuminuria and estimated glomerular filtration rate (eGFR); defining treatment outcomes; glycemic management in both those developing CKD and those with ESRD; hypertension goals and management, including blockers of The renin-angiotensin-aldosterone system; and lipid management.

AB - The incidence and prevalence of diabetes mellitus (DM) continue to grow markedly throughout The world, due primarily to The increase in type 2 DM (T2DM). Although improvements in DM and hypertension management have reduced The proportion of diabetic individuals who develop chronic kidney disease (CKD) and progress to end-stage renal disease (ESRD), The sheer increase in people developing DM will have a major impact on dialysis and transplant needs. This KDIGO conference addressed a number of controversial areas in The management of DM patients with CKD, including aspects of screening for CKD with measurements of albuminuria and estimated glomerular filtration rate (eGFR); defining treatment outcomes; glycemic management in both those developing CKD and those with ESRD; hypertension goals and management, including blockers of The renin-angiotensin-aldosterone system; and lipid management.

KW - Albuminuria

KW - blood pressure

KW - diabetic kidney disease

KW - glycemic control

KW - lipid management

UR - http://www.scopus.com/inward/record.url?scp=84920272288&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920272288&partnerID=8YFLogxK

U2 - 10.1038/ki.2014.128

DO - 10.1038/ki.2014.128

M3 - Article

C2 - 24786708

AN - SCOPUS:84920272288

VL - 87

SP - 20

EP - 30

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - 1

ER -

Diabetic kidney disease: A clinical update from Kidney Disease: Improving Global Outcomes

Abstract

Bibliographical note

Keywords

UN SDGs

Access

Other files and links

Cite this